Leah Jones
Psychiatry · Atlanta, GANPI 1821484288
Payments from drug & device makers
Across 427 payments — averaging $22.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Supernus Pharmaceuticals, Inc.$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$994
- AbbVie$953
- Tris Pharma Inc$814
- Otsuka America Pharmaceutical, Inc.$723
- Johnson & Johnson$627
- plus $4K from 23 others
What the payments were for
- Food & beverage$9,53299%
- Education$991%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Supernus Pharmaceuticals, Inc. | 54 | $1,719 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 45 | $994 |
| AbbVie | 42 | $953 |
| Tris Pharma Inc | 34 | $814 |
| Otsuka America Pharmaceutical, Inc. | 38 | $723 |
| Johnson & Johnson | 24 | $627 |
| Corium, LLC | 33 | $597 |
| Axsome Therapeutics, Inc. | 14 | $389 |
| Lundbeck LLC | 20 | $378 |
| Noven Therapeutics, LLC | 21 | $355 |
| Bausch Health US, LLC | 15 | $282 |
| Teva Pharmaceuticals USA, Inc. | 11 | $272 |
| Ironshore Pharmaceuticals Inc. | 12 | $257 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $241 |
| Neurocrine Biosciences, Inc. | 8 | $156 |
| Collegium Pharmaceutical, Inc. | 7 | $141 |
| Vanda Pharmaceuticals Inc. | 6 | $129 |
| Idorsia Pharmaceuticals US Inc | 6 | $108 |
| Alfasigma USA, Inc. | 6 | $92 |
| Merck | 4 | $66 |
| Sunovion Pharmaceuticals Inc. | 3 | $57 |
| Sandoz | 2 | $49 |
| Eisai Inc. | 3 | $49 |
| Brainsway USA Inc | 1 | $43 |
| Jazz Pharmaceuticals Inc. | 2 | $39 |
| Adlon Therapeutics L.p. | 2 | $31 |
| Alkermes, Inc. | 1 | $25 |
| Tempus AI, Inc | 1 | $24 |
| E.r. Squibb & Sons, L.L.C. | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- QELBREE$506
- VRAYLAR$245
- Dyanavel XR$121
- Quillivant$121
- Quillichew ER$121
- SPRAVATO$121
How this compares
$9,631 in reported general payments places this provider in the 90th percentile of 900 psychiatry providers in Georgia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 11 | $14,974 |
| TrintellixVortioxetine Hydrobromide | 16 | $7,083 |
| FetzimaLevomilnacipran Hcl | 12 | $5,587 |
| Vilazodone Hcl | 55 | $3,959 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 27 | $1,147 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 30 | $1,008 |
| Aripiprazole | 35 | $888 |
| Dextroamphetamine Sulfate | 13 | $701 |
| Bupropion XlBupropion Hcl | 12 | $508 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 25 | $383 |
| Clonazepam | 25 | $196 |
| Lamotrigine | 13 | $177 |
| Escitalopram Oxalate | 26 | $165 |
| Trazodone Hcl | 23 | $95 |
| Fluoxetine Hcl | 17 | $94 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar, Fetzima | $953 | $20,56123 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $241 | $7,08316 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 900 psychiatry providers in Georgia.
Other psychiatry in Atlanta
- Robert RiesenbergAtlanta$51.1M
- Saundra Maass-RobinsonAtlanta$11.1M
- David PurselleAtlanta$7.4M
- Bethany DavisAtlanta$4.4M
- Patricio Riva PosseAtlanta$884K
- Kerry ResslerAtlanta$365K
- Boadie DunlopAtlanta$345K
- Michael BurkeAtlanta$328K
- Bryon EvansAtlanta$211K
- Nurul HoqueAtlanta$145K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.